Click image to view original image
skype;Candice148722
whatsApp:8618038176817
if you are interested in my products,pls contact me,thanks
Quick Detail
|
Product name |
Tamoxifen citrate Factory Supplying |
|
Other name |
Nolvadex |
|
CAS register number |
54965-24-1 |
|
EINECS |
259-415-2 |
|
Molecular formula |
C32H37NO8 |
|
Molecular weight |
563.64 |
|
Molecular structure |
|
|
Melting point |
140-144 °C |
|
Assay |
99% |
Description:
Nolvadex (tamoxifen citrate) is very comparable to Clomid, behaves in the same manner in all tissues, Tamoxifen Citrate is a mixed estrogen agonist/antagonist of the same type as Clomid. The two molecules are also very similar in structure. Tamoxifen Citrate is not correct that Nolvadex reduces levels of estrogen: rather, Tamoxifen Citrate blocks estrogen from estrogen receptors and, in those tissues where it is an antagonist, causes the receptor to do nothing.
The claim that Nolvadex reduces gains should not be taken too seriously. The fact is that any number of bodybuilders have made excellent gains while using Nolvadex.
The belief that Tamoxifen Citrate reduces gains seems to stem from the fact that the scientific literature reports a slight reduction in IGF-1 (individuals using anabolic steroids were not studied though) from use of Nolvadex.
Thus, Dan Duchaine reported that Tamoxifen Citrate reduces IGF-1 and therefore reduces gains. However, if Tamoxifen Citrate this effect exists at all, Tamoxifen Citrate must be very minor, due to the excellent gains that many have made, and from the fact that no one has noticed any such thing from Clomid, which has the same activity profile.
The fact that Nolvadex will reduce water retention may result in the user agreeing thatTamoxifen Citrate gains are less, since weight gain is less, thus reinforcing the bias.
Specifications:
|
Product name |
Tamoxifen citrate (Nolvadex) |
|
|
Appearance |
White crystalline powder |
|
|
Identification |
IR , UV conform |
Conform |
|
Loss on drying |
≤0.5ml |
0.21ml |
|
Residue on ignition |
Not more than 0.2% |
0.06ml |
|
Iron |
Not more than 0.005% |
0.0018% |
|
Heavy metals |
Not more than 0.001% |
0.0006% |
|
Related substances |
Total: Not more than 1.0% |
0.32% |
|
E-isomer |
Not more than 0.3% |
0.19% |
|
Organic volatile impurities |
Conforms |
Conforms |
|
Assay |
99.0~101.0% |
99.51 |
COA and HPLC
|
Product name |
Tamoxifen citrate (Nolvadex) |
|
|
Appearance |
White crystalline powder |
|
|
Identification |
IR , UV conform |
Conform |
|
Loss on drying |
≤0.5ml |
0.21ml |
|
Residue on ignition |
Not more than 0.2% |
0.06ml |
|
Iron |
Not more than 0.005% |
0.0018% |
|
Heavy metals |
Not more than 0.001% |
0.0006% |
|
Related substances |
Total: Not more than 1.0% |
0.32% |
|
E-isomer |
Not more than 0.3% |
0.19% |
|
Organic volatile impurities |
Conforms |
Conforms |
|
Assay |
99.0~101.0% |
99.51% |
Applications:
Tamoxifen Citrate For the treatment of advanced, recurrent breast cancer and ovarian cancer and other illnesses. Tamoxifen Citrate Used as an antineoplastic raw materials.Biological Activity: Estrogen receptor antagonist/partial agonist. Selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
